Literature DB >> 6119104

Comparison of antianginal efficacy of one conventional and three long acting beta-adrenoreceptor blocking agents in stable angina pectoris.

G R Jones, M A Mir.   

Abstract

We compared the antianginal efficacy of one conventional and three long acting beta-adrenoreceptor blocking agents in a randomised manner in 12 patients with stable angina pectoris. An exercise test was performed initially and in the 24th hour after a single daily dose of 160 mg of each beta-blocker at the end of a two week treatment period. In addition, glyceryl trinitrate consumption, anginal attack rate, and activity scores were recorded. No titration studies to an equivalent degree of beta-blockade were undertaken; a fixed dose was used even though these drugs are not equipotent. Conventional propranolol in a single daily dose of 160 mg was as effective in controlling the frequency of anginal attacks as long acting propranolol and sustained release oxprenolol. Exercise tolerance was less with sustained release oxprenolol than with conventional propranolol, long acting propranolol, and nadolol. Nadolol produced a significantly greater reduction in exercise-induced tachycardia than did long acting propranolol, sustained release oxprenolol, and conventional propranolol, and also the lowest anginal attack rate, the lowest trinitrin consumption, and significantly less ST segment depression than the other three. These findings suggest that nadolol is more potent than long acting propranolol, sustained release oxprenolol, and conventional propranolol, and the antianginal benefit at the 24th hour relates to the degree of beta-adrenoreceptor blockade achieved.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6119104      PMCID: PMC482687          DOI: 10.1136/hrt.46.5.503

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  9 in total

1.  Correlation of plasma propranolol concentration with therapeutic response in patients with angina pectoris.

Authors:  M Pine; L Favrot; S Smith; K McDonald; C A Chidsey
Journal:  Circulation       Date:  1975-11       Impact factor: 29.690

2.  Pharmacology of nadolol (SQ 11725), a beta-adrenergic antagonist lacking direct myocardial depression.

Authors:  R J Lee; D B Evans; S H Baky; R J Laffan
Journal:  Eur J Pharmacol       Date:  1975 Sep-Oct       Impact factor: 4.432

3.  Effect of beta-blockers on exercise double product (systolic blood pressure x heart rate).

Authors:  R A Vukovich; J E Foley; B Brown; D A Willard; M Buckley; D O'Kelly; D Fitzgerald; W Tormey; A Darragh
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

4.  Propranolol in patients with angina pectoris.

Authors:  R E Gianelly; R H Goldman; B Treister; D C Harrison
Journal:  Ann Intern Med       Date:  1967-12       Impact factor: 25.391

5.  Importance of the design of an exercise protocol in the evaluation of patients with angina pectoris.

Authors:  D R Redwood; D R Rosing; R E Goldstein; G D Beiser; S E Epstein
Journal:  Circulation       Date:  1971-05       Impact factor: 29.690

6.  Propranolol in angina pectoris.

Authors:  T T Zsotér; D S Beanlands
Journal:  Arch Intern Med       Date:  1969-11

7.  Dose response effectiveness of propranolol for the treatment of angina pectoris.

Authors:  E L Alderman; R O Davies; J J Crowley; M G Lopes; J Z Brooker; J P Friedman; A F Graham; H J Matlof; D C Harrison
Journal:  Circulation       Date:  1975-06       Impact factor: 29.690

8.  Comparison of the immediate effects of five beta-adrenoreceptor-blocking drugs with different ancillary properties in angina pectoris.

Authors:  U Thadani; C Davidson; W Singleton; S H Taylor
Journal:  N Engl J Med       Date:  1979-04-05       Impact factor: 91.245

9.  Comparison of five beta-adrenoreceptor antagonists with different ancillary properties during sustained twice daily therapy in angina pectoris.

Authors:  U Thadani; C Davidson; W Singleton; S H Taylor
Journal:  Am J Med       Date:  1980-02       Impact factor: 4.965

  9 in total
  3 in total

1.  Concentration-effect relationships with FM 24: a new long acting beta-adrenergic receptor antagonist.

Authors:  C T Dollery; H J Dargie; J Sassard; G Cuisinaud
Journal:  Br J Clin Pharmacol       Date:  1983-06       Impact factor: 4.335

Review 2.  Pharmacokinetics of long acting propranolol. Implications for therapeutic use.

Authors:  G S Nace; A J Wood
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

3.  Effect of a long acting beta-adrenoceptor blocker on diurnal variation of cardiac dysrhythmias.

Authors:  M A Mir
Journal:  Postgrad Med J       Date:  1986-03       Impact factor: 2.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.